Exposure to Bovine Leukemia Virus Is Associated with Breast Cancer: A Case-Control Study

Gertrude Case Buehring1*, Hua Min Shen1, Hanne M. Jensen2, Diana L. Jin1, Mark Hudes3, Gladys Block4

1 Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, United States of America, 2 Department of Pathology and Laboratory Medicine, University of California, Davis Medical Center, Sacramento, California, United States of America, 3 Atkins Center for Weight and Health, University of California, Berkeley, California, United States of America, 4 Division of Community Health and Human Development, School of Public Health, University of California, Berkeley, California, United States of America

* buehring@berkeley.edu

Abstract

Background
Age, reproductive history, hormones, genetics, and lifestyle are known risk factors for breast cancer, but the agents that initiate cellular changes from normal to malignant are not understood. We previously detected bovine leukemia virus (BLV), a common oncogenic virus of cattle, in the breast epithelium of humans. The objective of this study was to determine whether the presence of BLV DNA in human mammary epithelium is associated with breast cancer.

Methods
This was a case-control study of archival formalin fixed paraffin embedded breast tissues from 239 donors, received 2002–2008 from the Cooperative Human Tissue Network. Case definition as breast cancer versus normal (women with no history of breast cancer) was established through medical records and examination of tissues by an anatomical pathologist. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Results
The frequency of BLV DNA in mammary epithelium from women with breast cancer (59%) was significantly higher than in normal controls (29%) (multiply-adjusted odds ratio = 3.07, confidence interval = 1.66–5.69, p = .0004, attributable risk = 37%). In women with premalignant breast changes the frequency of BLV DNA was intermediate (38%) between that of women with breast cancer and normal controls (p for trend < .001).
Conclusions
Among the specimens in this study, the presence of amplified BLV DNA was significantly associated with breast cancer. The odds ratio magnitude was comparable to those of well-established breast cancer risk factors related to reproductive history, hormones, and lifestyle and was exceeded only by risk factors related to genetics (familial breast cancer), high dose ionizing radiation, and age. These findings have the potential for primary and secondary prevention of breast cancer.

Introduction
Breast cancer begins as a change within mammary epithelial cells that starts them on an estimated 20–30 year course through stages of early precancerous changes, carcinoma in situ, and ultimately invasive cancer. Hereditary (familial) breast cancer accounts for fewer than 10% of cases [1]. Although risk factors for the remaining 90% of cases have been identified, including age, reproductive history, exogenous hormones, diet, exercise, alcohol consumption and other lifestyle factors, the exact agents responsible for the initial cellular/molecular changes are not fully understood. Ionizing radiation accounts for <1% of non-hereditary (sporadic) breast cancers [2], leaving the initiating agent for at least 90% of breast cancer cases unaccounted for.

Oncogenic viruses are implicated in at least 6 types of human cancer, the most established of which are hepatocellular carcinoma (hepatitis B and C viruses), carcinoma of the uterine cervix (oncogenic human papillomavirus [HPV] types), Burkitt’s lymphoma and nasopharyngeal carcinoma (Epstein-Barr virus), adult T-cell leukemia (human T-cell leukemia virus [HTLV-1]), and Kaposi’s sarcoma (human herpes virus 8) [3,4]. The longstanding interest in viral initiation of breast cancer stems from the mouse model, the only animal breast cancer with a known etiology. Its causative agent, mouse mammary tumor virus (MMTV), is a retrovirus transmitted from mother to pups via milk [5]. Over the past 50 years there has been considerable interest in determining whether MMTV or a closely related human virus might be transmitted via milk and play an important causative role in human breast cancer. Numerous investigations (1970–1985), found no convincing evidence of an MMTV-like virus in human milk or breast tissues. Although the search was revitalized by the advent of PCR and sequencing, results of the more recent investigations have been divergent and no consensus has been reached [6].

Most humans in Western cultures consume more cow’s milk products in a lifetime than they do human milk, which led us to investigate whether a bovine virus might be an initiating agent for breast cancer. The most prevalent oncogenic virus of cattle is bovine leukemia virus (BLV), a deltaretrovirus closely related to HTLV-1. BLV causes bovine leukemia (leukemia/lymphoma) of B cells [7]. Approximately 38% of beef herds, 84% of dairy herds, and 100% of large-scale dairy operation herds in the USA are infected with BLV [8,9]. Fewer than 5% of these cattle develop clinical leukemia, a condition that mandates exclusion from the US market. BLV-infected lymphocytes circulate through the blood of infected cattle. BLV also infects the mammary epithelial cells of cows [10] and infected cells may be found in cow’s milk [10,11], although pasteurization renders BLV noninfectious [12,13].

In a previous study, we tested humans for antibodies against BLV as a first step in determining if humans were BLV-infected. Using immunoblotting and purified recombinant p24 capsid protein as the target antigen, IgG antibodies were detected in 39% of 257 subjects [14].
To extend the serologic findings, we used in situ PCR to analyze human breast tissues, and detected BLV DNA (retrotranscribed from its RNA genome) in 97/219 (44%) specimens [15]. An independent laboratory validated these results on seven representative specimens [15]. DNA sequences derived from five BLV-positive specimens studied in depth were compared with sequences deposited in the National Center for Biotechnological Information (NCBI) GenBank. They matched sequences of BLV and no others [15]. They did not exhibit the unique signature mutation of our positive control cell line [15]. Using a monoclonal antibody, BLV capsid protein (p24) was detected in 6% of the 219 specimens by immunohistochemistry, suggesting that in some humans, BLV might not be in its usual latent state [16], and viral replication could be occurring.

Thus, in a previous study we have shown that BLV DNA and protein were present in some humans, and were localized primarily to mammary epithelium [15], the cell type from which most breast malignancies arise. We describe here an investigation to explore whether BLV in breast tissue is associated with breast cancer. We conducted a case-control study using malignant breast tissue samples from women with a diagnosis of breast cancer as cases, and nonmalignant breast tissue from women with no history of breast cancer as controls, and examined the association of breast cancer status with presence of retrotranscribed BLV DNA in mammary epithelium as a biomarker of exposure. We tested breast tissue specimens from 239 donors using in situ-PCR and targeting tax, the BLV genome region coding for the oncogenic protein responsible for malignant transformation [16]. In deltaretroviral genomes tax is rarely deleted during disease progression as are the genome regions related to viral replication (gag, pol, env) [16], and tax has the most highly conserved sequence of any deltaretroviral genome region [17]. We also tested the specimens for the presence of the BLV p24 capsid protein as a secondary method.

Methods
Specimen Acquisition and Evaluation
Coded breast tissues were acquired through the Cooperative Human Tissue Network, a National Cancer Institute supported tissue bank. Specimens were selected without regard to age, race/ancestry, or diagnosis, from a series of archived breast tissue chronologically acquired from females undergoing breast surgery (2002–2008) at participating hospitals in four catchment areas: Alabama, Pennsylvania, Ohio, and California. The majority (94%) of breast tissues from normal controls originated from reduction mammoplasties, whereas those from breast cancer patients were primarily from mastectomies. All donors gave informed consent for research use of their tissues, and the human use protocol was approved by the Committee for the Protection of Human Subjects, University of California, Berkeley. Information available for all donors was age, gender, date and type of surgery, history of invasive breast cancer, pathology of the specimen, and catchment area. The 114 donors categorized as cases had been diagnosed with invasive breast cancer. The 104 donors categorized as controls had normal breast tissue (free of malignant cells and any premalignant changes), and no previous history of invasive breast cancer. The 21 donors categorized as premalignant had tissue changes classified as premalignant [18] e.g. atypical ductal hyperplasia and carcinoma in situ, and no previous history of invasive breast cancer.

Tissues were formalin-fixed and paraffin embedded at the hospital of origin within 24 hours after surgery. Paraffin blocks were sectioned (4–5µm thick) by the Histopathology Reference Laboratory, Hercules, CA. One section from each sample was stained with hematoxylin and eosin as a reference slide, and the rest were mounted unstained on enhanced adherent slides (Fisher Scientific, #12-550-15). Each specimen was examined, the diagnosis confirmed, and the
area of each tissue and area occupied by mammary epithelium determined by our pathologist (HMJ). All samples were evaluated after in situ PCR to determine the pathology of the cell types that were BLV-positive. Tissue age (length of time in the formalin-fixed, paraffin-embedded state) was calculated as the difference in months, between the date of surgery and date of performance of in situ-PCR.

**In Situ Polymerase Chain Reaction (IS-PCR)** was used to detect BLV DNA in the tissue samples. It was based on methods described by Nuovo [19], and was used previously to detect BLV DNA in bovine [20], alpaca [21], and human tissues [15]. The positive control was the BLV-infected FLK (fetal lamb kidney) cell line [22], authenticated as a sheep cell line using species specific primers [23]. Primer sequences, below, were from the tax region of the BLV genome. The location of the tax primers used is shown below in base pair (bp) numbering according to GenBank accession #EF600696.

Forward (bp 7310–7329): ATGTCACCATCGATGCCTGG
Reverse (bp 7423–7404): CATCGGCCTCGCTCAGTGATA

Specificity of these primers for BLV was previously demonstrated by sequence alignments (NCBI BLAST) and lack of amplification of representatives of all oncogenic retroviruses, lentiviruses, as well as viruses reported present in human breast tissues (HERV-K, human papillomaviruses 16, 18, and Epstein-Barr virus) [15]. The in situ-PCR procedure involved incorporation of digoxigenin labeled dUTP into DNA within the fixed cells during one round of 30 cycles of PCR amplification. The incorporated label was then detected by anti-digoxigenin antibodies in an avidin-biotin-immunoperoxidase reaction (Roche). The chromagen was diaminobenzidine (Sigma). Outcome measurement was a semi-quantitative light microscopic judgment of brown color density of the cellular reactions (1+– 4+). See online S1 File for further methodology detail.

Specimens were scored positive for the presence of BLV DNA amplicons only if 1) rating of cellular reactions was ≥2; 2) positive and negative cell line controls had the appropriate reactions, pictured in our previous publication [15], which validated the in situ PCR methodology used here; 3) BLV-related amplicons were found in mammary epithelium (Fig 1A and 1B); and 4) the background control for non-specific tissue reactions (an adjacent tissue section reacted with the PCR mix minus primers) was negative for the corresponding area (Fig 1C). Specimens were scored blinded as to donor’s breast cancer status.

**Immunohistochemistry** was performed on formalin fixed deparaffinized tissue sections to identify BLV protein using a monoclonal antibody to the p24 capsid protein in an avidin-biotin-immunoperoxidase reaction. See online S1 File for the detailed procedure.

**Statistical Analysis**

Baseline differences between cases and controls were examined with chi square and t-test analyses. The association between BLV status and breast cancer was examined using unconditional multivariate logistic regression [24]. Adjusted models for the full sample included age, race/ancestry, and catchment area. We examined potential effect modification by donor age, race/ancestry and catchment area by including cross-product terms in the logistic model. Donors whose ancestry was unknown were combined with the Caucasian category because most donors from the same catchment area were of Caucasian ancestry. Area of mammary epithelium and duration as fixed samples were highly skewed and no transformation improved skewness. These variables were largely bimodal, with 90% or more of the samples falling in one group, and were examined in stratified analyses. Fit of the model was assessed using the Hosmer-Lemeshow Goodness of fit test [25]. Attributable risk was calculated as: \[
\frac{\text{[(proportion exposed among non-cases)(OR-1)]}}{\text{[(proportion exposed among non-cases)(OR-1) + 1]}} [24]
\]
Results

Characteristics of the 218 breast cancer cases and controls are shown in Table 1. Cases were significantly older, by four years at the median, and were predominantly of Caucasian ancestry. Both the amount of mammary epithelium and the length of time in a formalin-fixed state were greater among cases than controls. However, overall, 90% of all specimens had mammary epithelium of 36 mm² or less, and 93% of tissues had been in formalin-fixed state for fewer than 50 months (mean 10.8, SD 12.8 months). BLV positivity was strongly associated with race/ethnicity, and associated to a lesser degree with the other variables.

Presence of BLV-related DNA in breast tissue specimens was strongly associated with breast cancer (multiply-adjusted odds ratio = 3.07, confidence interval = 1.66–5.69, p = .0004, attributable risk = 37%) (Table 2). BLV was detected in the mammary epithelium of 59% of women diagnosed with breast cancer versus 29% of those with no history of breast cancer. BLV frequency in breast epithelium of women with premalignant changes (n = 21) was 38%, intermediate between the frequency in breast cancer cases and normal breast cancer-free controls (Fig 2).

Women of African ancestry had an overall frequency of breast tissue BLV of 29% (16/56), significantly lower (p < .01) than the BLV frequency in women of Caucasian ancestry (50%, 79/157) (Table 2). The association of BLV presence with breast cancer was weaker for women of African ancestry (OR = 1.87, CI = 0.50–7.03) than for women of Caucasian ancestry (OR = 3.71, CI = 1.80–7.61), and not statistically significant.

We conducted subgroup analyses to explore the possibility of uncontrolled confounding. Because cancer involves excessive cell proliferation, it was not surprising that some case samples contained larger areas of mammary epithelium than was found in most controls. The odds ratio among those with large samples could not be estimated, since almost all were cases. However, when we examined just the 90% of subjects with mammary epithelium of 36 mm² or less, the odds ratio for the association of presence of BLV DNA with breast cancer was 3.67 (95% CI 1.89–7.13), larger than but consistent with the odds ratio observed among all subjects, and suggesting that the overall finding was not due to an artifact of the amount of mammary epithelium.

Fig 1. Bovine leukemia virus (BLV) in the mammary epithelium of a donor with breast cancer. (A) BLV DNA detected by in situ PCR (brown cells) (X40). Note presence of brown outcome reaction only in epithelium and not in surrounding connective tissue; (B) enlargement of boxed area in A, showing that the positive reaction is localized to the cytoplasm of mammary epithelial cells (X136). (C) background control, adjacent section reacted with PCR mix without primers to rule out non-specific false positive reactions (X40). Note absence of brown outcome reaction. Counterstain for A,B, and C is Difquick blue.

doi:10.1371/journal.pone.0134304.g001
Table 1. Baseline characteristics of breast cancer cases and normal controls.

|                      | All Subjects (n = 218) | Cases (n = 114) | Controls (n = 104) | p¹ | Subjects BLV + (n = 97) | Subjects BLV− (n = 121) | p² |
|----------------------|------------------------|----------------|-------------------|----|------------------------|------------------------|----|
| Age                  |                        |                |                   |    |                        |                        |    |
| Mean (SD)            | 52.48(13.28)           | 55.9(14.1)     | 48.7(11.2)        |    | 54.6(13.89)            | 50.80(12.57)           |    |
| Median               | 51.00                  | 53.0           | 49.0              |    | 52.0                   | 50.0                   |    |
| Race³                |                        |                |                   |    |                        |                        |    |
| Caucasian or unknown | 157 (72.02)            | 87 (76.32)     | 70 (67.31)        |    | 79 (81.44)             | 78 (64.46)             |    |
| Other                | 61 (27.98)             | 27 (23.68)     | 34 (32.69)        |    | 18 (18.56)             | 43 (35.54)             |    |
| Catchment area       |                        |                |                   |    |                        |                        |    |
| Alabama              | 80 (36.70)             | 47 (41.23)     | 33 (31.73)        |    | 32 (32.99)             | 48 (39.67)             |    |
| Pennsylvania         | 103 (47.25)            | 47 (41.23)     | 56 (53.85)        |    | 45 (46.39)             | 58 (47.93)             |    |
| Ohio                 | 15 (6.88)              | 6 (5.26)       | 9 (8.65)          |    | 5 (5.15)               | 10 (8.26)              |    |
| Oakland, CA          | 20 (9.17)              | 14 (12.28)     | 6 (5.77)          |    | 15 (15.46)             | 5 (4.13)               |    |
| Tissue age⁵          |                        |                |                   |    |                        |                        |    |
| > 50 months          | 16 (7.34)              | 11 (9.65)      | 5 (4.81)          |    | 11 (11.34)             | 5 (4.13)               |    |
| ≤ 50 months          | 202 (92.66)            | 103 (90.35)    | 99 (95.19)        |    | 86 (88.66)             | 116 (95.87)            |    |
| Area of epithelium⁶  |                        |                |                   |    |                        |                        |    |
| > 36 sq.mm           | 21 (9.63)              | 20 (17.54)     | 1 (0.96)          |    | 11 (11.34)             | 10 (8.26)              |    |
| ≤ 36 sq.mm           | 197 (90.37)            | 94 (82.46)     | 103 (99.04)       |    | 86 (88.66)             | 111 (91.74)            |    |

Abbreviations: n = number; SD = standard deviation, sq. = square.
¹Significance of difference between cases and controls.
²Significance of difference between BLV+ and BLV−.
³Race/ancestry—patient’s self-classification in medical records. ‘Other’ includes 56 African Americans, 3 Asian Americans, 2 other race.
⁴Number of subjects (% of total in case and control categories).
⁵Tissue age—the time between initial formalin fixation and the performance of the in situ PCR assay.
⁶Area of epithelium—total area of mammary epithelium present in the breast tissue specimen.

doi:10.1371/journal.pone.0134304.t001

Table 2. Association between breast cancer and exposure to bovine leukemia virus.

|                      | Unadjusted | Adjusted¹ |
|----------------------|------------|-----------|
|                      | OR (95% CI)| p         | OR (95% CI)| p       |
| All subjects         |            |           |            |         |
| BLV +                | 67(59%)    | 30(29%)   | 3.52 (2.00–6.19) | < .0001 | 3.07 (1.66–5.69) | .0004 |
| BLV −                | 47(41%)    | 74(71%)   | 1.00⁵      |          | 1.00       |       |
| African American     |            |           |            |         |
| BLV +                | 9(39%)     | 7(21%)    | 2.39 (0.73–7.79) | .14     | 1.87 (0.50–7.03) | .35   |
| BLV −                | 14(61%)    | 26(79%)   | 1.00       |          | 1.00       |       |
| Caucasian/ Unknown   |            |           |            |         |
| BLV +                | 56(64%)    | 23(33%)   | 3.69 (1.90–7.17) | < .0001 | 3.71 (1.80–7.61) | .0004 |
| BLV −                | 31(36%)    | 47(67%)   | 1.00       |          | 1.00       |       |

¹ Logistic regression. Adjusted models include age, race and catchment area for All Subjects; age and catchment for Caucasian or Unknown; and only age for African Americans due to the small sample size. Further adjustment of All Subjects for large area of mammary epithelium or long-term storage increased the odds ratio.
²BLV negative subjects are the referent.

doi:10.1371/journal.pone.0134304.t002
We also examined the potential effect of duration of tissue storage, for which more cases than controls had long-term storage. In the 93% of subjects with tissue storage of fewer than 50 months, the odds ratio was 3.26 (95% CI 1.72–6.16) (data not shown), consistent with the odds ratio observed in the whole group and suggesting that the overall finding was not due to artifacts resulting from storage. Furthermore, an interaction term in the main model was not significant.

We also examined the role of age. Within every decade of age, cases had a higher proportion of subjects with exposure to BLV than did controls. More cases than controls had age > 80 years; in the 90% of subjects with age between 30 and 80 years, the odds ratio was 3.36 (95% CI 1.86–6.08), suggesting that age was not an important confounder.

We examined whether differences in catchment area could have influenced the result. Since two catchment areas were too small to conduct analyses separately, we repeated the analyses, each time dropping one of the four catchment areas. Each of the four resulting odds ratios was greater than 3.0 and statistically significant.

Most malignant specimens were moderately and poorly differentiated invasive ductal carcinomas; there were too few specimens in other malignant categories to determine their individual associations with BLV DNA. Of 52 subjects whose tissues contained both malignant and nonmalignant cells or who had paired malignant and nonmalignant samples, 36/52 (69%) demonstrated BLV-related DNA in nonmalignant mammary epithelium.

Among 114 cases, 82 had measurements of estrogen receptor (ER) and/or progesterone receptor (PR) status. BLV-related DNA was found more frequently in ER-positive samples (68%) than in ER-negative samples (50%) (p = .11), and more frequently (74%) in PR-positive than in PR-negative samples (51%) (p = .06). Presence of BLV p24 protein was detected in 12/236 (5%) of specimens. There were too few p24 positive specimens to determine if cases and controls differed significantly in p24 production.
Discussion

Presence of BLV-DNA in breast tissues was strongly associated with diagnosed and histologically confirmed breast cancer, OR = 3.07. As many as 37% of breast cancer cases may be attributable to BLV exposure. The odds ratio is comparable to that of commonly cited reproductive, hormone, and lifestyle risk factors for non-hereditary (sporadic) breast cancer (OR range = 1.2–2.0), and is exceeded only by risk factors related to genetics (familial breast cancer), high dose ionizing radiation, and age (OR range = 3.6–5.8) [26–31].

A comparison of different racial/ancestry groups was not part of our original experimental design but the conspicuously lower frequency of BLV DNA and breast cancer odds ratio in women of African versus Caucasian ancestry is worth mentioning and is consistent with the lower breast cancer incidence among African Americans after age 40, even though their mortality is higher [32,33]. The number of African American subjects (n = 56) in this study however, was limited and further research is necessary to substantiate these observations.

The finding of BLV-related DNA in breast tissues from 29% of normal women is not surprising considering the long latency period of breast cancer, an estimated 20–30 years from the initiating carcinogenic event(s) to appearance of a clinically detectable tumor [34,35], and the life cycle of deltaretroviruses (human, simian, and bovine leukemia viruses). Other oncogenic retroviral families, alpha, beta (to which MMTV belongs), and gamma, achieve oncogenesis by integration into host genomic DNA with perturbation of host protooncogenes and cellular growth control, a mechanism similar to that of endogenous human retroviruses to which beta and gamma retroviruses are closely related phylogenetically [36]. In contrast, deltaretroviruses, which are not closely related to any group of endogenous retroviruses [36], do not have to integrate in order to be oncogenic. BLV and its close relative HTLV-1 are usually found unintegrated in lymphocytes during asymptomatic and premalignant phases of bovine leukosis [37] and human T-cell leukemia [38], respectively. During advanced disease phases, when integration into host cell DNA may occur [37], the integration sites for BLV have been found to be random [39]. The oncogenic Tax proteins of BLV and HTLV-1 have been shown to inhibit base excision DNA repair [40,41], through interaction with checkpoint kinase 2 (Chk2) [42,43]. With the resulting decrease in DNA repair, infected cells could gradually, over the lifetime of the infected individual, accumulate unrepaired mutations caused by normal endogenous oxidative metabolism or by exogenous carcinogens, thereby increasing genomic instability, and potentially leading to malignancy. In this respect, deltaretroviruses are considered complex retroviruses, more closely resembling some oncogenic DNA viruses, e.g. hepatitis B virus and human papilloma virus (HPV), which produce an oncogenic protein coded by their own genome.

A well-accepted somewhat analogous cancer initiation mechanism is that of oncogenic types of HPV, which inhibit p53 function, thereby resulting in gradual accumulation of mutations and increasing genomic instability. Therefore, evidence of BLV in normal breast tissues prior to premalignant and malignant changes would be expected. According to the field cancerization theory, most cancers are rare events, developing over decades within a population of carcinogen-initiated cells widespread in a tissue [44,45]. This pattern is observed in carcinoma of the uterine cervix [46], in which the causative virus (HPV) is found not only in the malignant tissue, but also in premalignant dysplastic areas and in normal tissue adjacent to the malignant tumor. The field theory predicts that biomarkers of risk/causeation would precede transformation to malignancy, whereas biomarkers of advanced tumor progression, e.g. changes in chromosomes, estrogen and progesterone receptors, and HER2/neu status, would follow transformation to malignancy.
A recent study of the potential of next generation sequencing (massively parallel sequencing) to identify new viral agents of cancer resulted in data that argued against a viral etiology of human breast cancer based on analysis of transcriptome data [47]. However, since transcriptome data rests upon mRNA transcription, BLV was likely not detected because it is so latent in vivo that any mRNA produced would probably be below a detectable level. In previous studies of BLV-infected lymphocytes circulating in the blood of infected cattle with persistent lymphocytosis (a premalignant state), mRNA transcription was detected in only 1 in 50,000 infected cells [48].

How humans become infected with BLV is not known. Transmission from cattle to humans is plausible, as BLV is widespread in both beef herds and dairy herds [8,9]. Although pasteurization renders the virus non-infectious and presumably thorough cooking of beef also does, many people have drunk raw milk and/or eaten raw or undercooked beef at some point in their life. Breast cancer incidence is markedly higher in countries with high milk consumption [49–52]. Numerous prospective studies on dairy consumption in various defined populations [53], however, including one study that carefully evaluated unpasteurized milk consumption [54], found no significant relationship between cow’s milk consumption and breast cancer incidence. Human to human transmission is also plausible. Milk-borne transmission of BLV from cow to calf occurs naturally and HTLV, the human virus closely related to BLV, is transmitted primarily from nursing mother to child in endemic areas [55]. Epidemiologic studies on human breast milk consumption, however, have not found a significant increase in breast cancer among women who were ever breast-fed as infants compared with those who were never breast fed [56,57]. One potential challenge confronting the elucidation of BLV’s route of transmission to humans is the long agricultural association of humans with cattle, which began over 2,000 years ago, while milk pasteurization in western countries was not standard practice until around 1925 [58]. This would have allowed ample time for BLV to enter the human population and become established, yet still be reentering the human population under certain circumstances. The current reservoir for transmission to humans could, therefore, be cattle, humans, or both.

Strengths of this study include biological plausibility, the fact that a well studied animal model (mouse) demonstrated a viral causation of mammary cancer, and the previous demonstration that humans are, in fact, infected with BLV. Another strength is our observed gradient of breast tissue diagnosis in relation to frequency of BLV exposure: 59% of malignant tissues, 38% of tissues with premalignant changes, and 29% of tissues from normal controls were BLV positive (Fig 2).

There are also limitations. The validity of a case-control study depends on the assumption that the controls arise from the same population as that from which the cases arise. In this study, most case samples came from mastectomies for breast cancer, and most control samples came from reduction mammoplasties, which could represent different underlying populations. There were several geographical locations, and there were different race/ethnic groups, which could represent different underlying populations. While we cannot be sure that there aren’t unappreciated differences, we have gone to considerable lengths to assess the possibility that these or other factors were confounders. The association is unlikely to be an artifact of age differences, because we find the same association among younger women, and higher BLV positivity in cases than controls in each decade of age. It is unlikely to be due to racial differences between cases and controls, because we find the association in the 72% of the sample who are of Caucasian origin. The association is unlikely to be an artifact of the geographic location from which the samples arose, because we find the association in each of the two larger catchment areas, and also when we sequentially drop one of the four catchment areas. The observed association is unlikely to be due to the size of the available tissue sample or the length of tissue
storage, because we find the same association in the 90% of cases and controls with comparable tissue area and tissue storage.

It is a limitation of the in situ-PCR method upon which the study is based, that the PCR amplicon generated within the tissue DNA cannot be easily sequenced, as in standard PCR. However, our previous study, in which both in situ and solution PCR were performed on different portions of 5 positive specimens, indicated complete concordance of the two methods and >99% homology of sequenced amplicons with published BLV sequences. Contamination of standard solution PCR reactions with DNA of the positive control was ruled out by the absence of the control cell line’s signature mutation at base pair position 5194 [15]. A further strength of in situ PCR methodology is that molecular contamination cannot occur due to the composition of the PCR reaction mix, which differs from that used for standard solution, and allows amplification only within the cells, not in the PCR reaction mix covering the tissue during the reaction [19].

A case-control study is not conclusive in itself. Validation by other investigators is essential, and a prospective study showing that viral infection preceded detectable cancer development would be desirable to support the idea of a causal association of BLV with breast cancer [59]. Regardless of causality or of how the virus has been acquired by humans, if BLV were substantiated as a risk factor for breast cancer, its detection in breast fluid cells or tissues might serve as a biomarker to identify women at higher risk for developing breast cancer and perhaps warranting closer monitoring leading to early detection and treatment. Also since BLV is a retrovirus, the opportunity presents itself to explore the effectiveness of anti-retroviral therapy in limiting or eliminating BLV before breast cancer could be initiated.

Supporting Information

S1 File. Online Supplementary Methodology Information.

(DOCX)

Acknowledgments

We are grateful to Drs. Michael Bates, Julianne Deardorff, and Catherine Metayer, University of California, Berkeley, for critical review of the manuscript. We thank Drs. Steven Ruzin and Denise Schichnes, CNR Biological Imaging Facility, University of California, Berkeley for photography, and Dr. Kathryn Radke, University of California, Davis for supplying the BLV positive and negative control cell lines. We thank the Cooperative Human Tissue Network for being the source of the human specimens and accompanying donor information.

Author Contributions

Conceived and designed the experiments: GCB HMJ GB. Performed the experiments: HMS DLJ. Analyzed the data: GCB HMJ GB MH. Wrote the paper: GCB HMS HMJ DLJ GB.

References

1. American Cancer Society: Cancer Facts and Figures 2015. Atlanta: American Cancer Society; 2015.
2. Coyle YM. The effect of environment on breast cancer risk. Breast Cancer Res Treat 2004; 84:273–288. doi:10.1023/b:brea.0000019964.33963.09 PMID: 15026625
3. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature Rev Cancer 2010; 10:878–889. doi: 10.1038/nrc2961
4. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F et al. A review of human carcinogens-Part B: biological agents. Lancet 2009; 10:321–322. http://dx.doi.org/10.1016/s1470-2045(09)70096-8. PMID: 19350698
| No. | Reference |
|-----|-----------|
| 5.  | Robert-Guroff M, Buehring GC. In pursuit of a human breast cancer virus. In: Goedert JJ, ed. Viral, Bacterial, and Parasitic Oncology. Totowa, NJ: Humana Press; 2000:475–487. |
| 6.  | Salmons B, Gunzburg WH. Revisiting a role for a mammary tumor retrovirus in human breast cancer. Int J Cancer 2013; 133:1530–1555. doi: 10.1002/ijc28210 PMID: 23580334 |
| 7.  | Schwartz I, Lévy D. Pathobiology of bovine leukemia virus. Vet Res 1994; 25:521–536. PMID: 7889034 |
| 8.  | APHIS, Veterinary Service, Center for Epidemiology and Animal Health, USDA. Bovine leukemia virus (BLV) in U.S. beef cattle. Information Sheet, Feb 1999. |
| 9.  | APHIS, Bovine leukemia virus (BLV) on U.S. Dairy Operations, 2007. Oct. 2008; available on National Animal Health Monitoring System. High prevalence of BLV in US dairy herds. http://nahms.aphis.usda.gov/dairy/index.htm Accessed August 1, 2010. |
| 10. | Buehring GC, Kramme PM, Schultz RD. Evidence for bovine leukemia virus in the mammary epithelial cells of infected cows. Lab Invest 1994; 71:359–365. PMID:7933986 |
| 11. | Ferrer JF, Kenyon SJ, Gupta P. Milk of dairy cows frequently contains a leukemogenic virus. Science 1981; 213:1014–1016. doi:10.1126/science.6267692 PMID: 6267692 |
| 12. | Chung YS, Prior HC, Duffy PF, Rogers RJ, MacKenzie AR. The effect of pasteurization on bovine leukaosis virus-infected milk. Austral Vet J 1986; 63:379–380. PMID: 3030252 |
| 13. | Baumgartner L, Olson C, Onuma M. Effect of pasteurization and heat treatment on bovine leukemia virus. J Amer Vet Med Assc 1976; 169:1189–91. |
| 14. | Buehring GC, Philpott SM, Choi KY. Humans have antibodies reactive with bovine leukemia virus. AIDS Res Human Retroviruses 2003; 19:1105–1113. doi:10.1089/088922203771881202 |
| 15. | Buehring GC, Shen HM, Jensen HM, Choi KY, Sun D, Nuovo G. Bovine leukemia virus DNA in human breast tissue. Emerg Infect Dis 2014; 20:772–782. doi:10.3201/eid2005.131298 PMID: 24750974 |
| 16. | Gillett N, Florins A, Boxus M, Burateau AN, Vandermeers F, Balon H, et al. Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human. Retrovirology 2007; 4:18. doi:10.1186/1742-4690-4-18 PMID: 17362524 |
| 17. | Zhao X, McGirr KM, Buehring GC. Potential evolutionary influences on overlapping reading frames in the bovine leukemia virus pXBL region. Genomics 2007; 89:502–511. doi:10.1016/j.ygeno.2006.12.007 PMID: 17239558 |
| 18. | Fitzgibbons PL, Henson DE, Hutter RVP. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Arch Pathol Lab Med 1998; 122:1053–1055. PMID: 9870852 |
| 19. | Nuovo GJ. PCR in situ hybridization: Protocols and applications. Philadelphia, PA: Lippincott-Raven; 1996:193–244. |
| 20. | Duncan RB, Scarratt WK, Buehring GC. Detection of bovine leukemia virus by in situ polymerase chain reaction in tissues from a case of sporadic bovine lymphosarcoma. J Vet Diag Invest 2005; 17:190–194. doi:10.1177/104063870501700217 |
| 21. | Lee L, Scarratt WK, Buehring GC, Saunders GK. Bovine leukemia virus infection in a juvenile alpaca with multicentric lymphoma. Canav Vet J 2012; 53:283–286. |
| 22. | Van Der Maaten MJ, Miller JM. Replication of bovine leukemia virus in monolayer cell cultures. Bibl Haemato 1975; 43:360–362. |
| 23. | Cooper JK, Sykes G, King S, Cottril K, Ivanova NV, Hanner R, et al. Species identification in cell culture: a two pronged molecular approach. In Vitro Cell Dev Biol Anim 2007; 43:344–351. doi:10.1007/s11626-007-9060-2 PMID: 17934781 |
| 24. | Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. New York: Van Nostrand Reinhold, 1982. |
| 25. | Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989. |
| 26. | Singletary E., Rating the risk factor for breast cancer. Ann Surg 2003; 237:474–482. doi: 10.1097/01.sla.0000099699.64262.87 PMID: 12677142 |
| 27. | Clamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet 2002; 3:611–619. 3:611–619. doi: 10.1016/s1470-2045 (02)00875-6 PMID: 12372723 |
| 28. | Nelson HD, Humphry LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. J Amer Med Assc 2002; 288:872–881. doi: 10.1001/jama.288.7.872 |
| 29. | Brinton LA, Hoover R, Fraumeni JF. Reproductive factors in the etiology of breast cancer. Br J Cancer 1983; 47:757–762. PMID: 6860545 |
30. Trichopoulos D, McMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972; 48:605–613. PMID: 5058966
31. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin’s disease. Cancer Treat Rev 2000; 26:291–302. doi: 10.1053/ctrv.2000.0174 PMID: 10913384
32. Bondy ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi: 10.1002/cncr.11018
33. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
34. Lundgren B. Observations on growth rate of breast carcinomas and its possible implications for lead time. Cancer 2000; 40:722–25.
35. Von Fournier DV, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V. Growth rate of 147 mammary carcinomas. Cancer 1980; 45:2198–207. PMID: 7370960
36. De Parseval ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi:10.1002/cncr.11018
37. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
38. De Parseval ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi:10.1002/cncr.11018
39. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
40. De Parseval ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi:10.1002/cncr.11018
41. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
42. De Parseval ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi:10.1002/cncr.11018
43. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
44. De Parseval ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi:10.1002/cncr.11018
45. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
46. De Parseval ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi:10.1002/cncr.11018
47. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
48. De Parseval ML, Newman LA. Breast cancer risk assessment models: Applicability to African-American Women. Cancer (Suppl) 2000; 230–235. doi:10.1002/cncr.11018
49. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 2012; 104:1094–1101. doi: 10.1093/jnci/djs264 PMID: 22773826
50. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975; 15:617–631. PMID: 1140864
51. Globocan. Estimated age-standardized [breast cancer] incidence rate per 100,000, http://globcan.iarc.fr/map.asp?selection=3142&title=&se.
52. Chatstats. Current worldwide total milk consumption per capita. Available: http://chatstats.com/view/1491.
53. Dong J-Y, Zhang L, He K, Li-Qiang Q. Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies. Breast Cancer Research and Treatment 2011; 127:23–31. doi:10.1007/s10549-011-1467-5 PMID: 21442197

54. Sellers TA, Vierkant RA, Djeu J, Celis E, Wang AH, Kumar N, et al. Unpasteurized milk consumption and subsequent risk of cancer. Cancer Causes and Control 2008; 19:805–811. doi:10.1007/s10552-008-9143-8 PMID: 18344007

55. Lairmore MD. Animal models of bovine leukemia virus and human T-lymphotrophic virus-type-1: Insights in transmission and pathogenesis. Annu Rev Anim Biosci 2014; 2:189–208. doi:10.1146/annurev-animal-022513-114117 PMID: 25384140

56. Wise LA, Titus-Ernstnoff L, Newcomb PA, Trentham-Dietz A, Trichopoulos D, Hampton JM, et al. Exposure to breast milk in infancy and risk of breast cancer. Cancer Causes Control 2009; 20:1083–1090. doi:10.1007/s10552-009-9332-0 PMID: 19330531

57. Barba M, McCann SE, Nie J, Vito D, Stranges S, Fuhrman B, et al. Perinatal exposures and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control. 2006; 17:395–401. doi:10.1007/s10552-005-0481-5 PMID: 16596291

58. Carlson LW. Cattle: An informal social history. Chicago, IL: Ivan R. Dee; 2001.

59. Hill AB. The Environment and Disease: Association or Causation? Proc Royal Soc Med 1965; 58:295–300.